nach oben

European Archives of Oto-Rhino-Laryngology

Erschienen in:

01.07.2007 | Head and Neck

Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells

verfasst von: Takeharu Kanazawa, Hiroshi Nishino, Masahiro Hasegawa, Yasushi Ohta, Yukiko Iino, Keiichi Ichimura, Yutaka Noda

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

Interleukin-6 (IL-6) is a multifunctional regulator of immune response and hematopoiesis. Recently, it has been reported that expression of IL-6 is correlated with prognosis in various cancer patients. In this study, we investigated whether the proliferation and invasion potential of head and neck squamous cell carcinomas (HNSCCs) were influenced by IL-6. All HNSCC cell lines, HEp-2, HSC-2, HSC-4, and SAS, were tested by reverse transcription-polymerase chain reaction (RT-PCR) and expressed the IL-6 receptor (IL-6R), and glycoprotein 130, which is responsible for signal transduction. HEp-2, HSC-2, and HSC-4 also produced IL-6. IL-6 inhibited the proliferation of HSC-2 and SAS, but the invasion potential of all the cell lines increased. Moreover, IL-6 down-regulated soluble IL-6R expression. Anti-IL-6R antibody abrogated the inhibited proliferation and increased invasion induced by IL-6. IL-6 stimulation also induced the extracellular regulated protein kinase 1/2 activation and increased vascular endothelial growth factor release. These results suggest that IL-6 can directly influence cell proliferation and the invasion potential as the first step of tumor metastasis.

Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I, Lee JH (2003) Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 63:4648–4655PubMed

Raccurt M, Tam SP, Lau P, Mertani HC, Lambert A, Garcia-Caballero T, Li H, Brown RJ, McGuckin MA, Morel G, Waters MJ (2003) Suppressor of cytokine signalling gene expression is elevated in breast carcinoma. Br J Cancer 89:524–532PubMedCrossRef

Kishimoto T (1989) The biology of interleukin-6. Blood 74:1–10PubMed

Muraguchi A, Kishimoto T, Miki Y, Kuritani T, Kaieda T, Yoshizaki K, Yamamura Y (1981) T cell-replacing factor- (TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J Immunol 127:412–416PubMed

Mizutani H, May LT, Sehgal PB, Kupper TS (1989) Synergistic interactions of IL-1 and IL-6 in T cell activation. Mitogen but not antigen receptor-induced proliferation of a cloned T helper cell line is enhanced by exogenous IL-6. J Immunol 143:896–901PubMed

Gallagher G, Stimson WH, Findlay J, al-Azzawi F (1990) Interleukin-6 enhances the induction of human lymphokine-activated killer cells. Cancer Immunol Immunother 31:49–52PubMedCrossRef

Angelo LS, Talpaz M, Kurzrock R (2002) Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res 62:932–940PubMed

Takizawa H, Ohtoshi T, Ohta K, Yamashita N, Hirohata S, Hirai K, Hiramatsu K, Ito K (1993) Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res 53:4175–4181PubMed

Asschert JG, Vellenga E, Ruiters MH, de Vries EG (1999) Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int J Cancer 82:244–249PubMedCrossRef

10.

Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E (1993) Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 50:15–19PubMedCrossRef

11.

Pries R, Thiel A, Brocks C, Wollenberg B (2006) Secretion of tumor-promoting and immune suppressive cytokines by cell lines of head and neck squamous cell carcinoma. In Vivo 20:45–48PubMed

12.

Mann EA, Spiro JD, Chen LL, Kreutzer DL (1992) Cytokine expression by head and neck squamous cell carcinomas. Am J Surg 164:567–573PubMedCrossRef

13.

Chakravarti N, Myers JN, Aggarwal BB (2006) Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer 119:1268–1275PubMedCrossRef

14.

Woods KV, El-Naggar A, Clayman GL, Grimm EA (1998) Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. Cancer Res 58:3132–3141PubMed

15.

Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS (2003) Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 63:2948–2956PubMed

16.

Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, Philip T, Favrot M (1992) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52:3317–3322PubMed

17.

Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher LL, Van Waes C (1999) Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5:1369–1379PubMed

18.

Badache A, Hynes NE (2001) Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res 61:383–391PubMed

19.

Paysant J, Blanque R, Vasse M, Soria C, Soria J, Gardner CR (2000) Factors influencing the effect of the soluble IL-6 receptor on IL-6 responses in HepG2 hepatocytes. Cytokine 12:774–779PubMedCrossRef

20.

Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B (1995) Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 86:3123–3131PubMed

21.

Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 6:583–588PubMedCrossRef

22.

Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D Jr, Corey E (2003) Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97:1211–1216PubMedCrossRef

23.

Wellby ML, Kennedy JA, Pile K, True BS, Barreau P (2001) Serum interleukin-6 and thyroid hormones in rheumatoid arthritis. Metabolism 50:463–467PubMedCrossRef

24.

Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, Thijs LG, Aarden LA (1989) Increased plasma levels of interleukin-6 in sepsis. Blood 74:1704–1710PubMed

25.

Nishino H, Miyata M, Kitamura K (1998) The effect of interleukin-6 on enhancing the invasiveness of head and neck cancer cells in vitro. Eur Arch Otorhinolaryngol 255:468–472PubMedCrossRef

26.

Yoshizaki K, Nishimoto N, Matsumoto K, Tagoh H, Taga T, Deguchi Y, Kuritani T, Hirano T, Hashimoto K, Okada N, Kishimoto T (1990) Interleukin 6 and expression of its receptor on epidermal keratinocytes. Cytokine 2:381–387PubMedCrossRef

27.

Jourdan M, Veyrune JL, Vos JD, Redal N, Couderc G, Klein B (2003) A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 22:2950–2959PubMedCrossRef

28.

Okamoto M, Lee C, Oyasu R (1997) Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57:141–146PubMed

29.

Mihara M, Moriya Y, Ohsugi Y (1996) IL-6-soluble IL-6 receptor complex inhibits the proliferation of dermal fibroblasts. Int J Immunopharmacol 18:89–94PubMedCrossRef

30.

Oh JW, Katz A, Harroch S, Eisenbach L, Revel M, Chebath J (1997) Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells. Oncogene 15:569–577PubMedCrossRef

31.

Qiu Y, Ravi L, Kung HJ (1998) Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 393:83–85PubMedCrossRef

32.

Mizoguchi H, Komiyama S, Matsui K, Hamanaka R, Ono M, Kiue A, Kobayashi M, Shimizu N, Welgus HG, Kuwano M (1991) The response to epidermal growth factor of human maxillary tumor cells in terms of tumor growth, invasion and expression of proteinase inhibitors. Int J Cancer 49:738–743PubMedCrossRef

33.

Welch DR, Fabra A, Nakajima M (1990) Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 87:7678–76782PubMedCrossRef

34.

Chambers SK, Wang Y, Gertz RE, Kacinski BM (1995) Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res 55:1578–1585PubMed

35.

Noda I, Fujieda S, Ohtsubo T, Tsuzuki H, Tanaka N, Sunaga H, Saito H (1999) Granulocyte-colony-stimulating factor enhances invasive potential of human head-and-neck-carcinoma cell lines. Int J Cancer 80:78–84PubMedCrossRef

36.

Obata NH, Tamakoshi K, Shibata K, Kikkawa F, Tomoda Y (1997) Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res 17:337–342PubMed

37.

Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H, Herold-Mende C (2003) Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer 106:34–44PubMedCrossRef

38.

Yao JS, Zhai W, Young WL, Yang GY (2006) Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: the role for KDR and MMP-9. Biochem Biophys Res Commun 342:1396–404PubMedCrossRef

39.

Omori K, Naruishi K, Nishimura F, Yamada-Naruishi H, Takashiba S (2004) High glucose enhances interleukin-6-induced vascular endothelial growth factor 165 expression via activation of gp130-mediated p44/42 MAPK-CCAAT/enhancer binding protein signaling in gingival fibroblasts. J Biol Chem 279:6643–6649PubMedCrossRef

Titel: Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells
verfasst von: Takeharu Kanazawa
Hiroshi Nishino
Masahiro Hasegawa
Yasushi Ohta
Yukiko Iino
Keiichi Ichimura
Yutaka Noda
Publikationsdatum: 01.07.2007
Verlag: Springer-Verlag
Erschienen in: European Archives of Oto-Rhino-Laryngology / Ausgabe 7/2007
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-007-0264-6

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells

Abstract

Neu im Fachgebiet HNO

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Nur selten Nachblutungen nach Abszesstonsillektomie

Rezidivierender Peritonsillarabszess nach Oralsex

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2007

Auditory steady-state responses for estimating moderate hearing loss

Treatment of primary snoring using radiofrequency-assisted uvulopalatoplasty

Intraoral sebaceous carcinoma

Mast cells and T-lymphocytes in juvenile angiofibromas

The influence of measles vaccination on the incidence of otosclerosis in Germany

Skull base surgery for malignancy: when not to operate

Neu im Fachgebiet HNO

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Nur selten Nachblutungen nach Abszesstonsillektomie

Rezidivierender Peritonsillarabszess nach Oralsex

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update HNO